These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 10731530

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Evidence that the central noradrenergic and adrenergic pathways activate the hypothalamic-pituitary-adrenal axis in the sheep.
    Liu JP, Clarke IJ, Funder JW, Engler D.
    Endocrinology; 1991 Jul; 129(1):200-9. PubMed ID: 1647297
    [Abstract] [Full Text] [Related]

  • 23. Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions.
    Bernini GP, Argenio GF, Cerri F, Franchi F.
    J Endocrinol Invest; 1994 Nov; 17(10):799-804. PubMed ID: 7699214
    [Abstract] [Full Text] [Related]

  • 24. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution.
    Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, Labate AM, Barbara L.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):341-6. PubMed ID: 8393881
    [Abstract] [Full Text] [Related]

  • 25. The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
    Macut D, Božić Antić I, Nestorov J, Topalović V, Bjekić Macut J, Panidis D, Kastratović Kotlica B, Papadakis E, Matić G, Vojnović Milutinović D.
    Hormones (Athens); 2015 Aug; 14(1):109-17. PubMed ID: 25402380
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Adrenal steroid responses to naloxone in polycystic ovarian disease.
    D'Ambrogio G, Facchinetti F, Golinelli S, Setti T, Petraglia F, Genazzani AR.
    Gynecol Endocrinol; 1987 Dec; 1(4):355-61. PubMed ID: 2845715
    [Abstract] [Full Text] [Related]

  • 28. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T, Honour JW, Conway GS.
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [Abstract] [Full Text] [Related]

  • 29. Altered morning and nighttime pulsatile corticotropin and cortisol release in polycystic ovary syndrome.
    Invitti C, De Martin M, Delitala G, Veldhuis JD, Cavagnini F.
    Metabolism; 1998 Feb; 47(2):143-8. PubMed ID: 9472960
    [Abstract] [Full Text] [Related]

  • 30. Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome.
    Gonzalez F, Chang L, Horab T, Stanczyk FZ, Crickard K, Lobo RA.
    Fertil Steril; 1999 Mar; 71(3):439-44. PubMed ID: 10065779
    [Abstract] [Full Text] [Related]

  • 31. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA, Lewy V, Danadian K, Saad R.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [Abstract] [Full Text] [Related]

  • 32. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
    Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, Pasquali R, Walker BR.
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2295-302. PubMed ID: 16551740
    [Abstract] [Full Text] [Related]

  • 33. Pituitary-adrenal response in preterm very low birth weight infants after treatment with antenatal corticosteroids.
    Ng PC, Wong GW, Lam CW, Lee CH, Wong MY, Fok TF, Wong W, Chan DC.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3548-52. PubMed ID: 9360505
    [Abstract] [Full Text] [Related]

  • 34. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia.
    Pall M, Azziz R, Beires J, Pignatelli D.
    Fertil Steril; 2010 Jul; 94(2):684-9. PubMed ID: 19726039
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Gender differences in hypothalamic-pituitary-adrenal (HPA) axis reactivity.
    Uhart M, Chong RY, Oswald L, Lin PI, Wand GS.
    Psychoneuroendocrinology; 2006 Jun; 31(5):642-52. PubMed ID: 16616815
    [Abstract] [Full Text] [Related]

  • 37. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [Abstract] [Full Text] [Related]

  • 38. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism.
    Villa P, Valle D, Mancini A, De Marinis L, Pavone V, Fulghesu AM, Mancuso S, Lanzone A.
    Fertil Steril; 1999 Jan; 71(1):115-21. PubMed ID: 9935127
    [Abstract] [Full Text] [Related]

  • 39. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging.
    Wilkinson CW, Peskind ER, Raskind MA.
    Neuroendocrinology; 1997 Jan; 65(1):79-90. PubMed ID: 9032777
    [Abstract] [Full Text] [Related]

  • 40. Body-fat distribution and responsiveness of the pituitary-adrenal axis to corticotropin-releasing-hormone stimulation in sedentary and exercising women.
    Fabbri A, Giannini D, Aversa A, De Martino MU, Fabbrini E, Franceschi F, Moretti C, Frajese G, Isidori A.
    J Endocrinol Invest; 1999 May; 22(5):377-85. PubMed ID: 10401712
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.